Century Therapeutics (IPSC) to Release Quarterly Earnings on Wednesday

Century Therapeutics (NASDAQ:IPSC) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of ($0.0830) million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Century Therapeutics Trading Down 5.8%

Shares of Century Therapeutics stock opened at $2.77 on Wednesday. The stock has a fifty day simple moving average of $1.99 and a 200 day simple moving average of $1.07. Century Therapeutics has a 12-month low of $0.34 and a 12-month high of $3.04. The company has a market capitalization of $242.10 million, a P/E ratio of -8.66 and a beta of 1.70.

Insider Transactions at Century Therapeutics

In other Century Therapeutics news, insider Chad Cowan acquired 58,060 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were acquired at an average cost of $0.85 per share, with a total value of $49,351.00. Following the transaction, the insider owned 1,045,087 shares of the company’s stock, valued at $888,323.95. The trade was a 5.88% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Brent Pfeiffenberger purchased 52,000 shares of the stock in a transaction dated Friday, December 12th. The shares were acquired at an average cost of $0.58 per share, for a total transaction of $30,160.00. Following the completion of the acquisition, the chief executive officer owned 3,322,990 shares of the company’s stock, valued at approximately $1,927,334.20. This represents a 1.59% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 4.37% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Century Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in IPSC. Prudential Financial Inc. bought a new position in shares of Century Therapeutics during the 2nd quarter valued at approximately $25,000. Bank of America Corp DE grew its holdings in Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after buying an additional 34,466 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in Century Therapeutics during the 2nd quarter valued at approximately $38,000. Raymond James Financial Inc. bought a new stake in shares of Century Therapeutics during the second quarter valued at approximately $51,000. Finally, AQR Capital Management LLC raised its position in shares of Century Therapeutics by 358.9% during the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after buying an additional 86,875 shares during the last quarter. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on IPSC shares. Piper Sandler upped their price objective on Century Therapeutics from $2.00 to $4.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Zacks Research raised shares of Century Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 6th. TD Cowen assumed coverage on Century Therapeutics in a report on Wednesday, February 25th. They issued a “buy” rating on the stock. Leerink Partners downgraded shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 17th. Finally, Wall Street Zen upgraded Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $3.80.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.